Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-873-5 | CAS number: 100-63-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Additional information
Non-human data:
One study assessing the effects on fertility of phenylhydrazine was available. In this study each of three dogs (one dog per dose group) received 20, 30, or 40 mg phenylhydrazine/kg body weight in saline by subcutaneous injection on 2 consecutive days (Witchett, 1975). Two control animals were not injected. At necropsy, performed on all three animals within a few days of dosing, a “striking” reduction in spermatogenesis was reported, with an absence of sperm in the epididymis. However, the validity of this result was not clear, given the apparent extreme rapidity of the effect.
Human data:
No data available
Short description of key information:
One study was available assessing potential toxicity effects of phenylhydrazine on fertility.
Effects on developmental toxicity
Description of key information
Three studies were available assessing potential developmental toxicity effects by phenylhydrazine. Phenylhydrazine was not conclusively considered teratogenic.
Additional information
Non-human data:
In a teratogenicity study groups of 8–12 pregnant Wistar rats were given an intraperitoneal injection of 7.5 mg phenylhydrazine/kg body weight as phenylhydrazine hydrochloride on days 17, 18, and 19 of gestation; or 15 mg phenylhydrazine/kg body weight as phenylhydrazine hydrochloride on days 18 and 19 of gestation (Tamaki et al., 1974). Control animals were not treated. There was no reporting of maternal toxicity or of the effect of treatment on gestation or pup viability. Toxicity of the pups was reported only insofar as there was incidence of jaundice and/or anaemia among the offspring of treated animals. Twelve male offspring with severe jaundice and anaemia, selected from treated dams, and nine males from control dams were assessed at 9–22 weeks of age for functional and behavioural status. Although the authors reported that experimental animals showed statistically significant differences from controls in some tests, these findings are not considered to be reliable because of the small numbers of animals used and the exclusion of a control animal from the analysis. In addition, it is noted that only a brief part of the gestation period was covered by the treatment regime (days 17–19); no explanation is available for this choice of dosing regime.
In a second teratogenicity study intraperitoneal injection of pregnant rats with 15 mg phenylhydrazine/kg body weight as phenylhydrazine hydrochloride on days 18 and 19 of gestation produced hyperbilirubinaemia (resulting from haemolysis) in foetuses and newborns were reported (Yamamura et al., 1973).
In a third teratogenicity study to investigate behavioural changes on the rats from the dam treated with phenylhydrazine during pregnancy, groups of pregnant Wistar rats were given an intraperitoneal injection of 10 mg phenylhydrazine/kg body weight as phenylhydrazine hydrochloride on days 17, 18, and 19 of gestation; or 20 mg phenylhydrazine/kg body weight as phenylhydrazine hydrochloride on days 18 and 19 of gestation (Kiyono et al., 1974). Results showed no consistent difference between the experimental and control animals. However, the mean duration of the epoch of paradoxical sleep showed a significant decrease in several experimental rats, suggesting that this might be a sensitive indicator to detect the long-lasting functional disturbance caused by the toxic drug during the perinatal period.
Human data:
No data available
Justification for classification or non-classification
Based on available of results for reproductive and developmental toxicity, phenylhydrazine was not classified and labelled according to Directive 677548/EEC (DSD) and to Regulation 1272/2008/EC (CLP).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.